Pharmacist interventions on antibiotic use in inpatients with respiratory tract infections in a Chinese hospital

International Journal of Clinical Pharmacy

Volumn 33, Issue 6, 2011, Pages 929-933

  Shen, Jian ^a   Sun, Qingmin ^a   Zhou, Xianmei ^a   Wei, Yu ^a   Qi, Yongjian ^a   Zhu, Jiping ^a   Yan, Tingting ^b  

^a AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Antibiotic use; China; Pharmacist interventions; Respiratory tract infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFUROXIME; CEPHALOSPORIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULPERAZON;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHINESE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MEGADOSE; DRUG USE; FEMALE; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; INTERVENTION STUDY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; PHARMACY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SCORING SYSTEM; TERTIARY HEALTH CARE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHINA; DRUG COSTS; FEMALE; HOSPITAL COSTS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; PHYSICIAN'S PRACTICE PATTERNS; PROFESSIONAL ROLE; PROSPECTIVE STUDIES; RESPIRATORY TRACT INFECTIONS; YOUNG ADULT;

EID: 83255176736     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-011-9577-z     Document Type: Article

References (14)

1. Anderson RM. The pandemic of antibiotic resistance. Nat Med. 1999;5(2):147-9. (Pubitemid 29068516)
2. John JF Jr, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis. 1997;24(3):471-85. (Pubitemid 27096806)
3. Heddini A, Cars O, Qiang S, Tomson G. Antibiotic resistance in China - a major future challenge. Lancet. 2009;373(9657):30.
4. Reynolds L, McKee M. Factors influencing antibiotic prescribing in China: an exploratory analysis. Health Policy. 2009;90(1): 32-6.
5. von Gunten V, Reymond JP, Beney J. Clinical and economic outcomes of pharmaceutical services related to antibiotic use: a literature review. Pharm World Sci. 2007;29(3):146-63. (Pubitemid 46872977)
6. Weller TMA, Jamieson CE. The expanding role of the antibiotic pharmacist. J Antimicrob Chemother. 2004;54(2):295-8. (Pubitemid 39177444)
7. Zhu M, Guo DH, Liu GY, Pei F, Wang B, Wang DX, et al. Exploration of clinical pharmacist management system and working model in China. Pharm World Sci. 2010;32(4):411-5.
8. Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44(3): 357-63. (Pubitemid 46147617)
9. Hung MN, Hsueh PR, Chang HT, Lee WS, Chou MY, Chen IS, et al. In vitro activities of various piperacillin and sulbactam combinations against bacterial pathogens isolated from Intensive care units in Taiwan: SMART 2004 programme data. Int J Antimicrob Agents. 2007;29(2):145-52.
10. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27(1):10-22.
11. Al-Momany NH, Al-Bakri AG, Makahleh ZM, Wazaify MM. Adherence to international antimicrobial prophylaxis guidelines in cardiac surgery: a Jordanian study demonstrates need for quality improvement. J Manag Care Pharm. 2009;15(3):262-71.
12. Vogel F. Intravenous/oral sequential therapy in patients hospitalised with community-acquired pneumonia: which patients, when and what agents? Drugs. 2002;62(2):309-17. (Pubitemid 34169436)
13. Zhang R, Eggleston K, Rotimi V, Zeckhauser RJ. Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Global Health. 2006;2:6.
14. Deuster S, Roten I, Muehlebach S. Implementation of treatment guidelines to support judicious use of antibiotic therapy. J Clin Pharm Ther. 2010;35(1):71-8.